Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;60(13):3161-3171.
doi: 10.1080/10428194.2019.1616186. Epub 2019 May 21.

The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes

Affiliations

The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes

Mikkael A Sekeres et al. Leuk Lymphoma. 2019 Dec.

Abstract

Myelodysplastic syndromes (MDS), a spectrum of heterogeneous hematopoietic stem cell diseases, vary in clinical severity, response to therapy, and propensity toward progression to acute myeloid leukemia. These are acquired clonal disorders resulting from somatic mutations within the hematopoietic stem or progenitor cell population. Understanding the natural history and the risk of developing leukemia and other adverse outcomes is dependent on access to well-annotated biospecimens linked to robust clinical and molecular data. To facilitate the acquisition and distribution of MDS biospecimens to the wider scientific community and support scientific discovery in this disease, the National MDS Natural History study was initiated by the National Heart, Lung, and Blood Institute (NHLBI) and is being conducted in collaboration with community hospitals and academic medical centers supported by the National Cancer Institute (NCI). The study will recruit up to 2000 MDS patients or overlapping myeloproliferative neoplasms (MDS/MPN) and up to 500 cases of idiopathic cytopenia of undetermined significance (ICUS). The National MDS Natural History Study (NCT02775383) will offer the world's largest disease-focused tissue biobank linked to longitudinal clinical and molecular data in MDS. Here, we report on the study design features and describe the vanguard phase of 200 cases. The study assembles a comprehensive clinical database, quality of life results, laboratory data, histopathology slides and images, genetic information, hematopoietic and germline tissues representing high-quality biospecimens and data from diverse centers across the United States. These resources will be available to the scientific community for investigator-initiated research.

Keywords: Myelodysplastic syndromes; biorepository; natural history; quality of life.

PubMed Disclaimer

Conflict of interest statement

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2019.1616186.

Figures

Figure 1.
Figure 1.
Image acquisition and storage. Pathologist preview slides and mark areas of highest cellularity prior to imaging the Wright-Giemsa slide. The H&E stained bone marrow biopsy is imaged in its entirety. Slides are imaged with an Aperio AT2 digital whole slide scanner (Leica Biosystems Inc., USA) through a 20x/0.75NA objective lens with an optical doubler lens to bring magnification to 40x. Whole slide images are created in SVS file format at a compression ratio of 15–20:1 and stored on secure network drive that is backed up twice daily. Images were accessed through a password-restricted database called Eslide Manager version 12.3.3.5049 (Leica Microsystems Inc, USA).

Comment in

  • Banking on a cooperative effort.
    Chung SS. Chung SS. Leuk Lymphoma. 2019 Dec;60(13):3102-3103. doi: 10.1080/10428194.2019.1654098. Epub 2019 Aug 21. Leuk Lymphoma. 2019. PMID: 31432734 No abstract available.

References

    1. Jacobs RH, Cornbleet MA, Vardiman JW, et al. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood. 1986;67:1765–1772. - PubMed
    1. Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol. 2008;83:765–770. - PubMed
    1. Greenberg P, Anderson J, de Witte T, et al. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol. 2000;18:3447–3452. - PubMed
    1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088. - PubMed
    1. Maes B, Meeus P, Michaux L, et al. Application of the International Prognostic Scoring System for myelodysplastic syndromes. Ann Oncol. 1999;10:825–829. - PubMed

Publication types

MeSH terms